Misoprostol for prevention of postpartum hemorrhage

A randomized clinical trial of sublingual versus rectal misoprostol for the prevention of postpartum hemorrhage in low resource settings

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201802003154375

Enrollment

600

Registered

2018-02-27

Start date

2018-03-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Prevention of PPH

Interventions

Group 1 (Sublingual group)

Group 2 (Rectal group)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Pregnant women at term in active labour admitted to delivery room, with singleton pregnancy, vertex presentations with no risk factors for postpartum hemorrhage.

Exclusion criteria

Exclusion criteria: Grand multipara, operative vaginal delivery, previous uterine scar, contraindication to misoprostol or any risk factor for postpartum hemorrhage as multiple pregnancy, polyhydramnios and fetal macrosomia.

Design outcomes

Primary

Measure	Time frame
Amount of blood loss;postpartum hemorrhage;the need for injectable uterotonics;drop in Hemoglobin level after 24 hours;drug adverse effects	—

Countries

Egypt

Contacts

Public ContactMohamed Rezk

Assistant Professor of Obstetrics and Gynecology

m_rezk9207@yahoo.com00201006237186

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026